Results on Merck's new painkiller draw mixed reviews
13th Nov 2006, 15:09 GMT
CHICAGO - The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication's approval.
Results on Merck's new painkiller draw mixed reviews related news:
- Results on Merck's new painkiller draw mixed reviews — New Jersey News
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
Latest news from azcentral.com | business:
- Zune will take on iPod
- Sensor chips may transform familiar devices
- Filing is hard for owners
- Chamber CEO's effort draws cheers
- (Gasp!) Greenspan sometimes fumbles his forecasts for the economy
- Make character your best characteristic
- Mesa's S'Bistro pins hopes on downtown renaissance
- CEO discusses hospital's growth
- Commerce chief begins trip to promote more U.S. exports to China
- Online service offers cab shares with social twist in NYC